| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 6, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 6, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - Picard Medical, Inc. (0002030617) (Issuer)
PRE 14A - Picard Medical, Inc. (0002030617) (Filer)
424B3 - Picard Medical, Inc. (0002030617) (Filer)
EFFECT - Picard Medical, Inc. (0002030617) (Filer)
TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress, being held February 15th - 18th, 2026 in Barcelona, Spain. Details of the pres
TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company's fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. Schuster will review preclinical experience with SynCardia's next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System's / Picard Medical's